Article Text

Download PDFPDF
CASE REPORT
Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3′-deoxy-3′[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation
  1. Kalevi Kairemo1 and
  2. Vivek Subbiah2
  1. 1 Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2 Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  1. Correspondence to Dr Vivek Subbiah, vsubbiah{at}mdanderson.org

Abstract

Primary cardiac angiosarcoma, the most common primary cardiac sarcoma has an incidence ranging from 0.001% to 0.028% in autopsy reports with around 200 cases reported in literature. Since a diagnosis of cardiac angiosarcoma portends a poor prognosis, it is vital to ascertain the precise extent of the lesions for follow-up. Imaging with positron emission tomography (PET) tracer 2-deoxy-2-[18F]-fluoro-D-glucose in cardiac angiosarcoma is challenging as myocardium takes up glucose and delineation of tumour becomes difficult. Cell proliferation rate in normal cardiac muscular tissue is low whereas cardiac tumours display a higher proliferation rate. This aspect could be exploited by use of 3′-deoxy-3′[(18)F]-fluorothymidine positron emission tomography (18F-FLT PET/CT] in cardiac tumours where the cell proliferation could be measured. Herein, we imaged an index case of cardiac angiosarcoma using 18F-FLT PET/CT and report the findings.

  • oncology
  • carcinogenesis
  • radiology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors KK and VS conceived the manuscript, analysed the data, wrote the paper, critically revised and edited the manuscript. Both of the authors have (1) substantial contributions to the conception or design of the work; the acquisition, analysis, interpretation of data for the work; (2) drafting the work or revising it critically for important intellectual content and (3) final approval of the version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Next of kin consent obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.